The advent of targeted therapy has revolutionized the field of oncology, offering a more personalized approach to cancer treatment. Unlike conventional chemotherapy, which indiscriminately targets rapidly dividing cells, targeted therapies aim to interfere with specific molecules necessary for tumor growth and progression.
Targeted therapies can be broadly classified into two categories: small molecules and monoclonal antibodies. Small molecules are low-weight compounds that can penetrate the cell membrane and interact with intracellular targets. Monoclonal antibodies, on the other hand, are large proteins that cannot cross the cell membrane and are designed to target extracellular or cell surface molecules.
Targeted therapies work by blocking the growth signals of cancer cells, interfering with angiogenesis, promoting apoptosis, or enhancing the immune response against cancer cells. They have the advantage of being more selective, hence causing fewer side effects than traditional chemotherapy.
Despite the promising results of targeted therapies, challenges remain. These include the development of resistance, the high cost of these therapies, and the difficulty in identifying appropriate molecular targets. However, ongoing research and technological advancements promise to overcome these obstacles and broaden the application of targeted therapies in cancer treatment.
Targeted therapy represents a significant advancement in modern oncology, offering a more tailored approach to cancer treatment. By specifically targeting cancer cells, these therapies minimize damage to healthy cells and reduce side effects. Despite existing challenges, the potential of targeted therapies is vast and continues to be explored in ongoing research. As healthcare professionals, staying abreast of these developments is crucial to provide the best care for our patients.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation